Last reviewed · How we verify

NCT05962892

A Study of Factors Influencing Recurrence After Thermal Ablation of Papillary Thyroid Carcinoma

Recruiting now Last updated 30 January 2024
What this trial tests

trial testing No Intervention in Papillary Thyroid Carcinoma in 600 participants. Currently enrolling.

Timeline
1 February 2024
Primary endpoint
28 February 2028
28 February 2028

Quick facts

Lead sponsorBeijing Friendship Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment600
Start date1 February 2024
Primary completion28 February 2028
Estimated completion28 February 2028
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Friendship Hospital

Who can join

18 and older, any sex, with Papillary Thyroid Carcinoma or Thermal Ablation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective cohort of papillary thyroid carcinoma(PTC), patients who received thermal ablation in our hospital since February 2023 was established as the study object. Preoperative and postoperative demographic data, ultrasonography, other relevant laboratory tests, and thyroid disease-related scales such as fatigue, depression, and stress were collected. The influencing factors of PTC recurrence were analyzed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No Intervention

Trials testing the same drug.

Other recruiting trials for Papillary Thyroid Carcinoma

Currently open trials in the same condition.

Other Beijing Friendship Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05962892.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing